Vaccine for HER2-positive breast cancer after standard treatment
Part of Cancer, Skin clinical trials.
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had HER2-positive breast cancer (stages I, II, or III) and completed treatment with trastuzumab (Herceptin) and other standard therapies.
- You had residual cancer after neoadjuvant therapy, or you had stage III cancer with a complete response.
- You can start the study vaccine within 1 year after finishing trastuzumab and other treatments.
- No evidence of remaining breast cancer currently.
- You are in good general health (ECOG score 0-2) and have adequate organ function.
- You must live in the same country as the trial site and have been treated there.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.